Cargando…

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy

Detalles Bibliográficos
Autores principales:	Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Briasoulis, Alexandros, Gumeni, Sentiljana, Malandrakis, Panagiotis, Papanagnou, Eleni-Dimitra, Migkou, Magdalini, Kanellias, Nikolaos, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Letters to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8736278/ https://www.ncbi.nlm.nih.gov/pubmed/34986251 http://dx.doi.org/10.1182/blood.2021014989

Ejemplares similares

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA
por: Terpos, E, et al.
Publicado: (2022)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
por: Terpos, Evangelos, et al.
Publicado: (2021)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
por: Theodorakakou, Foteini, et al.
Publicado: (2023)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Terpos, Evangelos, et al.
Publicado: (2022)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
por: Terpos, Evangelos, et al.
Publicado: (2020)

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2022)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2023)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Emerging treatment strategies for COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
por: Rosati, Margherita, et al.
Publicado: (2022)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients
por: Kanellias, Nikolaos, et al.
Publicado: (2022)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
por: Kastritis, Efstathios, et al.
Publicado: (2023)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
por: Malandrakis, Panagiotis, et al.
Publicado: (2023)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
por: Terpos, Evangelos, et al.
Publicado: (2023)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
por: Papatsirou, Maria, et al.
Publicado: (2023)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uatgtliv4f6oi5g4csk72ga3sb